Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran for Secondary VTE Prevention in Children
NCT02197416Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of dabigatran etexilate oral solution in venous thromboembolism (VTE), sponsored by Boehringer Ingelheim. Primary endpoints: Event-free Probability of Recurrence of Venous Thromboembolism at 12 months, Event-free Probability of Major or Minor (Including Clinically Relevant Non-major) Bleeding Events at 12 months and 1 more. Started Sep 2014; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02197416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197416.